Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 19/20 | 0.60 |
| ▸ | PLA2G1B | P04054 | 8/20 | 0.60 |
| ▸ | PLA2G10 | O15496 | 7/20 | 0.60 |
| ▸ | PLA2G2E | Q9NZK7 | 7/20 | 0.60 |
| ▸ | PLA2G2D | Q9UNK4 | 6/20 | 0.60 |
| ▸ | PLA2G5 | P39877 | 5/20 | 0.60 |
| ▸ | PLA2G2F | Q9BZM2 | 5/20 | 0.60 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.54 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.54 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.54 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.54 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283147 | 0.94 | PLA2G2A (0.61) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G2D | |
| SCHEMBL6288180 | 0.90 | PLA2G2A (0.73) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G2D | |
| SCHEMBL6288136 | 0.78 | PLA2G2A (0.40) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G2D | |
| SCHEMBL14608056 | 0.76 | PLA2G2A (0.86) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G2D | |
| Water SCHEMBL5159364 | 0.76 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G2D | |
| Water SCHEMBL5159370 | 0.76 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G2D | |
| SCHEMBL5157654 | 0.75 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G2D | |
| SCHEMBL8033803 | 0.75 | PLA2G2A (0.64) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G2D | |
| SCHEMBL8035701 | 0.75 | PLA2G2A (0.64) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G2D | |
| SCHEMBL6812616 | 0.75 | PLA2G2A (0.82) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930123-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-16 | — | — | US | claimed |
| US-20040059130-A1 | Spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-03-25 | — | — | US | claimed |
| US-6930123-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040059130-A1 | Spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1349832-A2 | SUBSTITUTED BENZOINDOLES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002050028-A2 | SUBSTITUTED BENZOINDOLES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059130-A1 | Spla2 inhibitors | F2RL1, SPINT2, PLAAT2 | PLA2G2A 31/4885PLA2G1B 18/4885PLA2G10 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.